INTRODUCTION: Elderly @entity1 with @entity463 ( @entity463 ) are frequently excluded from @entity5 therapy trials, treated suboptimally or not treated at all. The average survival in elderly @entity1 is 4-8 months. The goal of the present study was to evaluate the efficacy of different treatment options in terms of survival in an elderly population affected with @entity463 . MATERIALS AND METHODS: About 34 @entity1 with primary supratentorial @entity463 aged 65 or higher were included in this study. All @entity1 underwent craniotomy and @entity5 mass resection. After surgery they received radiation therapy, chemotherapy and radioimmunotherapy in different combinations. RESULTS: Overall median survival was 10.5 months with one @entity1 still alive at 35 months. Survival was longer for @entity1 who underwent total resection instead of partial (13 months vs 4 months, P=0.006). If total en-bloc resection was used a further survival advantage was obtained (16 months for en-bloc resection, 9 months for inside-out resection, P=0.008). Where a second surgical intervention was performed median survival was 21 months (P=0.05). Survival according to adjuvant therapy has been 21 months (radiotherapy, chemotherapy, radioimmunotheraphy), 18 months (radiotherapy, chemotherapy) and 7 months (radiotherapy) (P=0.0001). CONCLUSIONS: We think that single prognostic factor such as age should be not a reason for undertreatment.

XXXX multiforme in the elderly: a therapeutic challenge.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity463 :: ('MESH:D005909', 'Disease') :: ['glioblastoma multiforme', 'GBM'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer']
@entity463 :: (MESH:D005909,Disease) :: ['Glioblastoma']
